<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04881396</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL21_0125</org_study_id>
    <secondary_id>2021-A00325-36</secondary_id>
    <nct_id>NCT04881396</nct_id>
  </id_info>
  <brief_title>Response of Haemodialysis Patients to BNT162b2 mRNA Cov-19 Vaccine</brief_title>
  <acronym>ROMANOV</acronym>
  <official_title>Response of Haemodialysis Patients to BNT162b2 mRNA Cov-19 Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vaccination against SARS-Cov2 is a necessity for haemodialysis patients because difficulties&#xD;
      to maintain a self-isolation (leading to a higher contamination than general population) and&#xD;
      an increase of mortality in case of contamination (more than 20% of mortality in this&#xD;
      population). However, vaccine efficiency is known to be decreased in haemodialysis patients.&#xD;
      This lead critical the rapid description of immunogenicity of anti SARS-Cov2 vaccine in&#xD;
      haemodialysis patients.&#xD;
&#xD;
      The aim of this study is to describe the immunogenicity of the BTN162b2 SARS-Cov2 vaccine in&#xD;
      haemodialysis patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 10, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Seroconversion rate after vaccination with BTN162b2 mRNA cov-19 vaccine</measure>
    <time_frame>The seroconversion rate is evaluated at Day 7-Day 14 after the second dose.</time_frame>
    <description>IgG anti SARS-Cov2 spike protein will be evaluated by ELISA at Day 0 (at the initiation of vaccination) anti Day 7 - Day 14 after the second dose (peak of response).&#xD;
The seroconversion is defined by an 4 fold increase of IgG anti SARS-Cov2 spike protein titer between Day 0 and Day 7 - Day 14 after second dose.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>COVID-19 Vaccines</condition>
  <condition>Hemodialysis Complication</condition>
  <arm_group>
    <arm_group_label>All haemodialysed patients with a medical prescription of BTN162b2 mRNA Cov-19 vaccine</arm_group_label>
    <description>Serological response is defined by a 4 fold increase of IgG anti-spike protein of SARS-Cov2 between Day 0 (before vaccination) and after complete vaccination (evaluated at Day 7 - 14 post-boost).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Evaluation of the immunogenicity of the vaccine in haemodialysis patients</intervention_name>
    <description>The immunogenicity of the vaccine will be evaluated at the peak of vaccine response (Day 7 - Day 14 after the second dose) and 6 and 12 months post vaccination, by the evaluation of humoral IgG anti-spike protein response (seroconversion rate, absolute antibody titers, affinity of antibody) and cellular anti SARS-Cov2 response (number, activation capacity, production of interferon gamma of CD4 and CD8 anti sars cov2 specific T cells)</description>
    <arm_group_label>All haemodialysed patients with a medical prescription of BTN162b2 mRNA Cov-19 vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated by chronic haemodialysis, with initiation of a vaccination by BTN162b2&#xD;
        mRNA Cov-19 with classical scheme&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Medical prescription of BTN162b2 mRNA Cov-19 vaccine&#xD;
&#xD;
          -  Treatment by chronic (&gt;1 month) haemodialysis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-recommended vaccination scheme&#xD;
&#xD;
          -  Refusal to consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Olivier THAUNAT, MD-PhD</last_name>
    <phone>0472115213</phone>
    <phone_ext>+33</phone_ext>
    <email>olivier.thaunat@chu-lyon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Nephrology, Hopital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Olivier Thaunat, MD-PhD</last_name>
      <phone>0472115213</phone>
      <phone_ext>+33</phone_ext>
      <email>Olivier.thaunat@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Caroline Pelletier, MD-PhD</last_name>
      <phone>0472110167</phone>
      <phone_ext>+33</phone_ext>
      <email>caroline.pelletier02@chu-lyon.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Department of Nephrology, Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre BÃ©nite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Laetita Koppe</last_name>
      <phone>0472678709</phone>
      <phone_ext>+33</phone_ext>
      <email>Laetitia.koppe@chu-lyon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 4, 2021</study_first_submitted>
  <study_first_submitted_qc>May 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2021</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immunogenicity</keyword>
  <keyword>haemodialysis patients</keyword>
  <keyword>SARS-Cov2 vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

